- Conditions
- Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Pazopanib, Temozolomide, Trabectedin, Transthoracic Echocardiography Test
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 120 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 146
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, Rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Cetuximab, Paclitaxel, Carboplatin, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- Accelerated Community Oncology Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 84
- States / cities
- Anniston, Alabama • Jonesboro, Arkansas • Anaheim, California + 81 more
- Conditions
- Melanoma, Cutaneous Malignant
- Interventions
- IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel
- Biological · Drug
- Lead sponsor
- Immatics US, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more
- Conditions
- Non Squamous Lung Cancer
- Interventions
- treatment
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 84
- States / cities
- Beverly Hills, California • Fontana, California • Loma Linda, California + 53 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Tislelizumab, Durvalumab, Ociperlimab, Chemotherapy, Radiotherapy
- Drug · Radiation
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Bolivar, Missouri
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab, NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI, Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI, Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI, Carboplatin + Nab-paclitaxel + Atezolizumab + NAI, Pembrolizumab, Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab, Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab, Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab, Carboplatin and Nab-paclitaxel plus Atezolizumab, Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 31
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more
- Conditions
- Gastric Cancer, Adenocarcinoma of the Gastroesophageal Junction
- Interventions
- Pembrolizumab, Standard of care chemotherapy regimen
- Drug
- Lead sponsor
- Gulam Manji
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • New York, New York • Providence, Rhode Island
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- pembrolizumab/vibostolimab, durvalumab, cisplatin, pemetrexed, etoposide, carboplatin, paclitaxel, thoracic radiotherapy
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 21
- States / cities
- Long Beach, California • Los Angeles, California • Hollywood, Florida + 18 more
- Conditions
- 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
- Interventions
- GVAX Pancreas Vaccine, CRS-207, Chemotherapy, cyclophosphamide
- Biological · Drug
- Lead sponsor
- Aduro Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • La Jolla, California • San Francisco, California + 16 more
- Conditions
- Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
- Interventions
- Olverembatinib, Investigator's choice of TKI
- Drug
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 11 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Lenvatinib, Pembrolizumab, Docetaxel, Capecitabine, Paclitaxel, Cetuximab
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 55
- States / cities
- Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more
- Conditions
- Rectal Adenocarcinoma
- Interventions
- Chemoradiation, short course radiation therapy, mFOLFOX6, CAPOX, fluoropyrimidine +/- oxaliplatin
- Other · Radiation · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Gastric, or Gastroesophageal Junction Adenocarcinoma
- Interventions
- Tislelizumab, Placebo, Cisplatin, Oxaliplatin, Capecitabine, 5-Fluorouracil
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 997 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 6
- States / cities
- Sacramento, California • Newnan, Georgia • Columbus, Ohio + 3 more
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
- Interventions
- Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 829
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 549 more
- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin, Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, Topotecan, Gemcitabine
- Biological · Drug
- Lead sponsor
- Mural Oncology, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 31 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Olaparib, 5-FU, Bevacizumab, Capecitabine, Leucovorin/ levoleucovorin
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 23
- States / cities
- Burbank, California • Fullerton, California • Colorado Springs, Colorado + 19 more
- Conditions
- Bladder Cancer
- Interventions
- Sacituzumab tirumotecan, Vinflunine, Docetaxel, Paclitaxel, Rescue medications for sacituzumab tirumotecan, Rescue medications for chemotherapy
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 16
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 13 more
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Olaparib, Placebo for olaparib, Etoposide, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Thoracic Radiotherapy, Durvalumab
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 33
- States / cities
- Mobile, Alabama • Jonesboro, Arkansas • Fullerton, California + 28 more
- Conditions
- Untreated Follicular Lymphoma
- Interventions
- Surovatamig, R-CHOP, R-CVP, BR
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,018 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 59
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
- Conditions
- High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma
- Interventions
- Pembrolizumab, Paclitaxel, Carboplatin, Avastin, MK-4830, Docetaxel
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 8 more
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Ifinatamab deruxtecan, Docetaxel, Paclitaxel, Irinotecan hydrochloride (HCl)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Fullerton, California • Orange, California + 10 more
- Conditions
- Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
- Interventions
- Alisertib, Pralatrexate, Gemcitabine, Romidepsin
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • La Jolla, California • Orlando, Florida + 21 more